Olema Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Indicates management contract or compensatory plan or arrangement
† The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act, irrespective of any general incorporation language contained in any such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Olema Pharmaceuticals, Inc. | ||
| Date: May 13, 2025 | By: | /s/ Sean Bohen, M.D., Ph.D. |
|---|---|---|
| Sean Bohen, M.D., Ph.D. | ||
| President and Chief Executive Officer(Principal Executive Officer) | ||
| Date: May 13, 2025 | By: | /s/ Shane Kovacs |
| Shane Kovacs | ||
| Chief Operating and Financial Officer(Principal Financial Officer and Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.